Study shows decrease in pneumonia rate since pediatric approval of vaccine
ATLANTA According to a study by the Centers for Disease Control and Prevention, since the PCV7 vaccine for pneumococcal bacteria was approved for children aged 5 and under in 2000, rates for invasive pneumococcal disease in all age groups have decreased significantly.
“This vaccine is continuing to provide a very substantial public health impact 6 years after its introduction. We estimate that between 2001 and 2006, 170,000 cases and 9,800 deaths were prevented as a result of this vaccine,” says Matthew Moore of the CDC, a lead researcher on the study. The CDC has been tracking the incidence of IPD, the most severe form of the disease – defined as meningitis or a bloodstream infection, which can include some cases of pneumonia – since the introduction of the vaccine.
The researchers found a significant decline in IPD rates for all age groups (78 percent decrease in children under 5 years; a 38 percent decrease in children and adolescents aged 5-17 years; a 39 percent decrease in adults aged 18-49 years; a 14 percent in people aged 50-64 years; a 32 percent decrease in adults 65-79 years; and a 42 percent in adults 80 years and older) with even greater declines in IPD caused by those strains included in the PCV7 vaccine.
The drug has an effect on so many age groups because of the spread of the bacteria from children to others.
QLT to sell off Aczone following FDA decision
VANCOUVER, Canada QLT has announced that it will proceed with its plan to sell its topical acne treatment Aczone after the Food and Drug Administration removed key blood monitoring requirements for the treatment, according to Reuters.
The company is selling the drug as part of a multi-step process to return it to its core business of treating eye diseases. Recently the company had been delving into acne and prostate cancer treatments.
Already several companies have expressed interest in Aczone and QLT predicts the drug will be sold within the next quarter or two.
Safeway offers Shingles vaccination
PLEASANTON, Calif. Safeway is offering immunization against Shingles, a disease that commonly affects people over 50 or people with compromised immune systems, at 700 pharmacies in the states of Ark., Calif., Colo., Del., Hawaii, Ind., Ill., Mont., Neb., Nev., Ore., Pa., Texas, Va. ,W.Va. and Wash. The vaccine will be provided on a walk-in basis at in-store pharmacies.
“The only way to prevent against contracting this debilitating disease is to get a single shot. By administering vaccines on site, Safeway is making it easy for anyone to protect themselves,” said Dave Fong, Safeway senior vice president of pharmacy. “Receiving a shingles vaccination is as easy as stopping at the pharmacy during your regular shopping trip.”
Safeway also offers full-service adult and adolescent immunization services for the prevention of such ailments as tetanus, hepatitis, pneumococcal, meningococcal and more.